CN1241442A - Post-operation adhesion preventing method - Google Patents

Post-operation adhesion preventing method Download PDF

Info

Publication number
CN1241442A
CN1241442A CN 99115039 CN99115039A CN1241442A CN 1241442 A CN1241442 A CN 1241442A CN 99115039 CN99115039 CN 99115039 CN 99115039 A CN99115039 A CN 99115039A CN 1241442 A CN1241442 A CN 1241442A
Authority
CN
China
Prior art keywords
adhesion
surgery
acid
adhesions
group
Prior art date
Application number
CN 99115039
Other languages
Chinese (zh)
Inventor
朱晓明
Original Assignee
林代平
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 林代平 filed Critical 林代平
Priority to CN 99115039 priority Critical patent/CN1241442A/en
Publication of CN1241442A publication Critical patent/CN1241442A/en

Links

Abstract

The degradable and absorbable polymer or copolymer material of lactic acid-glycollic acid copolymer, poly-D,L-lactic acid, poly-L-lactic acid and polyglycollic acid is machined at 180-220 deg.C into 0.0002-0.5mm thick film. The film after being disinfected is used in preventing post-operation adhesion, and this can reduce post-operation complication, raise cure effect of the operation and reduce pain of the patient.

Description

术后防粘连方法 Postoperative anti-adhesion method

本发明涉及一种术后防粘连方法,具体涉及采用生物可降解吸收性聚合物作为术后防粘膜的方法。 The present invention relates to a method for postoperative adhesion prevention, particularly relates to a method of a biodegradable polymer as the absorbent after the release film is used.

术后粘连是有手术史以来国内外尚未解决的重要课题之一。 Postoperative adhesions is an important issue since the surgery has yet to be resolved at home and abroad. 它常可以引起严重并发症,如腹部、盆腔手术后引起粘连性肠梗阻,开颅手术后可致术后癫痫,甲状腺术后可致继发性喉返神经损伤等,它也是使需二次手术并发症明显升高的主要原因,如肠道、胆管损伤、喉神经及甲状旁腺损伤等。 It can often lead to serious complications, such as abdominal, pelvic surgery causing intestinal obstruction, can cause epilepsy after craniotomy surgery, thyroid surgery can cause secondary recurrent laryngeal nerve injury, it is also required to make secondary the main reason for surgical complications was significantly higher, such as the intestine, bile duct injury, laryngeal nerve and parathyroid injury. 在预防术后粘连的研究中,过去仅限于腹腔手术预防粘连性肠梗阻。 In the study of prevention of postoperative adhesions in abdominal surgery in the past only to prevent adhesive intestinal obstruction. 人们曾经用腹腔内留置硅油,中分子右旋糖酐及链激酶等方法,但均无明显效果,或有副作用。 It had been indwelling silicone oil, and molecular dextran method intraperitoneal streptokinase, but had no significant effect, or side effects. 硅油不能被人体吸收,尽管对机体刺激性小,但由于长期留于腹腔内,产生刺激可引起渗出而导致继发性粘连。 Silicone oil can not be absorbed by the body, although little irritation to the body, but due to the long stay in the abdominal cavity, can cause irritation and bleeding leading to secondary adhesions. 中分子左旋糖酐由于是高渗,对组织有刺激性,使组织充血水肿,渗出增加而致粘连。 Since the molecular levulose anhydride is hypertonic, irritating to tissue, tissue edema, exudation caused increased adhesion. 链激酶是从留置于腹腔内的多孔小管注入,以期溶解纤维蛋白,但由于只能小量注入,管孔可被堵塞,及小管易位等诸多因素,疗效也不显著。 Streptokinase is indwelling in at a small tube into the peritoneal cavity in order to dissolve fibrin, but since only a small injection hole can be plugged, and translocation tubules and many other factors, the effect was not significant. 至今为止,国内外均未见到一种安全有效的防粘连方法报导。 So far, at home and abroad were not seen an effective and safe anti-adhesion method reported.

本发明的目的是采用一种新的术后防粘连方法,以克服现有技术的缺陷,达到方便、安全、有效防粘连的目的。 Object of the present invention is the use of a new anti-adhesion after ways to overcome the deficiencies of the prior art, to achieve convenient, safe, effective anti-adhesion purposes.

本发明的目的是采用以下方案来实现的。 Object of the present invention is achieved using the following protocol.

本发明采用粘均分子量<50万,下述生物可降解吸收性聚合物:PLGA(聚乳酸——聚乙醇酸共聚物)、PDLLA(聚-D,L-乳酸)、PLLA(聚-L-乳酸)、PGA(聚乙醇酸)中的任意一种材料或一种材料与另一种材料的共聚物在温度180~220℃加工成厚度为0.0002~0.5毫米的薄膜,经消毒,灭菌处理,用于术后防粘连。 The present invention employs a viscosity average molecular weight <500,000, following a biodegradable absorbent polymer: PLGA (polylactic acid - glycolic acid), of PDLLA (poly--D, L- lactic acid), of PLLA (poly -L- lactic acid), copolymers of any one material or one material (polyglycolic acid) PGA in another material working at a temperature of 180 ~ 220 ℃ a thickness of 0.0002 to 0.5 mm thin film, sterilized, sterilization for preventing postoperative adhesions.

本发明可以采用各种高分子材料膜成型工艺,将生物可降解吸收性聚合物在温度180~220℃加工成手术所需厚度的薄膜,如吹塑成形工艺,模板成形工艺等。 The present invention may employ various polymeric membrane forming process, the thickness of the biodegradable film is processed into a desired absorbent polymer at a temperature of 180 ~ 220 ℃ surgery, such as blow molding process, the template forming process and the like.

手术实施过程为:1.常规手术准备;2.常规手术操作;3.将生物膜按实际需要的面积剪下,覆盖于各层手术创面的表面(必要时可用手术线,稍加固定)。 Surgical procedure is implemented: 1 General surgical preparation; 2 conventional surgery operation; 3 biofilm cut according to the area actually required to cover the surface layers of the surgical wound (available surgical thread, if necessary, slightly fixed).... 4.常规结束手术。 4. General procedure ends.

本发明所述术后防粘连方法,采用PLGA、PGA、PDLLA、PLLA生物可降解吸收性聚合物为防粘膜,经安全性实验和动物实验证明,由这些材料制成薄膜具有优良的柔软性,可降解吸收性;良好的组织相容性,固定于防粘连部位创面,以防止其与外围组织粘连,不仅可防止腹腔内肠粘连,而且可防止肝脏脏面、肝门肝十二脂肠韧带的粘连,甲状腺术的食道粘连(咽紧缩感),开颅手术的蛛网膜下腔的粘连,盆腔脏器的粘连(输卵管、子宫卵巢)、胸腔的胸膜粘连等,可有效减少手术并发症,避免了再次手术,提高了手术疗效,减少了病人痛苦,节省了医疗费用,确实是一种方便,安全有效的术后防粘连方法。 The method of the present invention after antiblocking using PLGA, PGA, PDLLA, PLLA biodegradable absorbent polymer is a release film, the safety experiments and animal experiments show that these materials into a film having excellent flexibility, the absorbent biodegradable; good tissue compatibility, anti-blocking portion is fixed to the wound, to prevent tissue adhesion with the peripheral, not only prevents intraperitoneal adhesions and prevents the dirty surface of the liver, hepatic portal liver duodenum ligament adhesions, adhesions thyroid surgery of the esophagus (throat tightness), craniotomy subarachnoid adhesions, pelvic organ adhesions (fallopian tube, ovary and uterus), pleural pleural adhesions, which can effectively reduce surgical complications, avoiding re-operation to improve the surgery and reduce the suffering of patients and save health care costs, it is indeed a convenient, safe and effective after anti-adhesion method.

下面是本发明的实施例。 The following are examples of the present invention.

实施例一采用模板成形的方法,将分子量30万的PLGA0.5kg,在温度200℃±5℃下加工成厚度为0.0002~0.5毫米的薄膜,经环氧乙烷消毒、灭菌处理,用于预防椎板切除后硬膜周围纤维化与粘连以及肌腱手术、肠道手术、胆道手术术后防粘连,人体及动物实验结果见表1~2。 Example employed a method of forming a template, a molecular weight of 300,000 PLGA0.5kg, at a temperature of 200 ℃ ± 5 ℃ processed to a thickness of 0.0002 to 0.5 mm thin film, sterilized by ethylene oxide sterilization process for prevention of adhesions and fibrosis laminectomy tendon surgery, bowel surgery, biliary tract surgery postoperative adhesion prevention of human and animal experiment results shown in Table 1 and 2 surrounding dura.

实施例二采用吹塑成形的方法,将分子量25万的PLGA0.5kg,在温度190℃±5℃范围内加工成厚度为0.0002~0.5毫米的薄膜,经环氧乙烷消毒、灭菌处理,用于预防椎板切除后硬膜周围纤维化与粘连以及肌腱手术、肠道手术、胆道手术术后防粘连。 According to a second embodiment of the blow molding method, molecular weight 250,000 PLGA0.5kg, a temperature in the range of 190 ℃ ± 5 ℃ processed to a thickness of 0.0002 to 0.5 mm film, the ethylene oxide sterilization, sterilization, for around dural adhesions and fibrosis, tendon surgery, bowel surgery, biliary tract after laminectomy anti-adhesion prevention. 人体及动物实验结果见表1-2。 Human and animal experimental results are shown in Table 1-2.

实施例三采用模板成形的方法,将分子量20万的PDLLA0.5kg,在温度190℃±5℃范围内加工成厚度为0.0002~0.5毫米的薄膜,经环氧乙烷消毒、灭菌处理,用于预防椎板切除后硬膜周围纤维化与粘连以及肌腱手术、肠道手术、胆道手术术后防粘连,人体及动物实验结果见表1-2。 Third Embodiment template molding method, molecular weight 200,000 PDLLA0.5kg, a temperature in the range of 190 ℃ ± 5 ℃ processed to a thickness of 0.0002 to 0.5 mm film, the ethylene oxide sterilization, sterilization, with after laminectomy prevention of fibrosis and adhesions around the dura mater and tendon surgery, bowel surgery, postoperative biliary surgical anti-adhesion, human and animal experimental results are shown in Table 1-2.

实施例四采用吹塑成形的方法,将分子量20万的PDLLA0.5kg,在温度210℃±5℃范围内加工成厚度为0.0002~0.5毫米的薄膜,经环氧乙烷消毒、灭菌处理,用于预防椎板切除后硬膜周围纤维化与粘连以及肌腱手术、肠道手术、胆道手术术后防粘连,人体及动物实验结果见表1-2。 Fourth Embodiment blow molding method, a molecular weight of 200,000 PDLLA0.5kg, a temperature in the range of 210 ℃ ± 5 ℃ processed to a thickness of 0.0002 to 0.5 mm film, the ethylene oxide sterilization, sterilization, for the prevention laminectomy surrounding dural adhesions and fibrosis, tendon surgery, bowel surgery, biliary tract surgery postoperative adhesion prevention of human and animal experiment results shown in Table 1-2.

实施例五采用模板成形的方法,将分子量40万的PLLA0.5kg,在温度205℃±5℃范围内加工成厚度为0.0002~0.5毫米的薄膜,经环氧乙烷消毒、灭菌处理,用于预防椎板切除后硬膜周围纤维化与粘连以及肌腱手术、肠道手术、胆道手术术后防粘连,人体及动物实验结果见表1-2。 According to a fifth embodiment of the method forming the template, a molecular weight of 400,000 PLLA0.5kg, a temperature in the range of 205 ℃ ± 5 ℃ processed to a thickness of 0.0002 to 0.5 mm film, the ethylene oxide sterilization, sterilization, with after laminectomy prevention of fibrosis and adhesions around the dura mater and tendon surgery, bowel surgery, postoperative biliary surgical anti-adhesion, human and animal experimental results are shown in Table 1-2.

实施例六采用吹塑成形的方法,将分子量40万的PLLA0.5kg,在温度210℃±5℃范围内加工成厚度为0.0002~0.5毫米的薄膜,经环氧乙烷消毒、灭菌处理,用于预防椎板切除后硬膜周围纤维化与粘连以及肌腱手术、肠道手术、胆道手术术后防粘连,人体及动物实验结果见表1-2。 Sixth Embodiment blow molding method, a molecular weight of 400,000 PLLA0.5kg, a temperature in the range of 210 ℃ ± 5 ℃ processed to a thickness of 0.0002 to 0.5 mm film, the ethylene oxide sterilization, sterilization, for the prevention laminectomy surrounding dural adhesions and fibrosis, tendon surgery, bowel surgery, biliary tract surgery postoperative adhesion prevention of human and animal experiment results shown in Table 1-2.

实施例七采用模板成形的方法,将分子量18万的PGA0.5kg,在温度190℃±5℃范围内加工成厚度为0.0002~0.5毫米的薄膜,经环氧乙烷消毒、灭菌处理,用于预防椎板切除后硬膜周围纤维化与粘连以及肌腱手术、肠道手术、胆道手术术后防粘连,人体及动物实验结果见表1-2。 According to a seventh embodiment of the method forming the template, molecular weight 180,000 PGA0.5kg, a temperature in the range of 190 ℃ ± 5 ℃ processed to a thickness of 0.0002 to 0.5 mm film, the ethylene oxide sterilization, sterilization, with after laminectomy prevention of fibrosis and adhesions around the dura mater and tendon surgery, bowel surgery, postoperative biliary surgical anti-adhesion, human and animal experimental results are shown in Table 1-2.

实施例八采用吹塑成形的方法,将分子量18万的PGA0.5kg,在温度200℃±5℃下加工成厚度为0.0002~0.5毫米的薄膜,经环氧乙烷消毒、灭菌处理,用于预防椎板切除后硬膜周围纤维化与粘连以及肌腱手术、肠道手术、胆道手术术后防粘连,人体及动物实验结果见表1-2。 Blow molding method, molecular weight 180,000 PGA0.5kg embodiment eight embodiment, at a temperature of 200 ℃ ± 5 ℃ processed to a thickness of 0.0002 to 0.5 mm film, the ethylene oxide sterilization, sterilization, with after laminectomy prevention of fibrosis and adhesions around the dura mater and tendon surgery, bowel surgery, postoperative biliary surgical anti-adhesion, human and animal experimental results are shown in Table 1-2.

实施例九将分子量均为40万的PDLLA-PLGA共聚物0.8kg,混合均匀后采用吹塑成型的方法,在温度205℃±5℃范围内加工成厚度为0.0002~0.5毫米的薄膜,经环氧乙烷消毒、灭菌处理,进行人体及动物术后防粘连实验,其防粘结果见表1~2。 The molecular weight of 400,000 are nine of PDLLA-PLGA copolymer 0.8kg, mixed uniformly using the method of Example blow molding, a temperature in the range of 205 ℃ ± 5 ℃ processed to a thickness of 0.0002 to 0.5 mm film, via a ring ethylene oxide sterilization, sterilization treatment, and anti-blocking human experimental animals after its release results shown in Table 1-2.

实施例十将分子量为45万的PLLA-PDLLA共聚物0.6kg混合均匀后采用模板成型的方法,在温度195℃±5℃下加工成厚度为0.0002~0.5毫米的薄膜,经消毒灭菌处理,进行人体及动物术后防粘连实验,其防粘效果见表1-2。 The tenth embodiment of the molding method using template 450,000 molecular weight copolymer of PLLA-PDLLA 0.6kg mixed, at a temperature of 195 ℃ ± 5 ℃ processed to a thickness of 0.0002 to 0.5 mm thin film, sterilized treated, human and anti-adhesion experiments carried out after the animals, releasing its results in Table 1-2.

实施例十一将分子量为35万的PDLLA-PGA共聚物0.5kg混合后采用吹塑成型工艺,在温度200℃±5℃下加工成厚度为0.0002~0.5毫米的薄膜,经消毒灭菌处理,用于人体及动物术后防粘连实验,其效果见表1-2。 Example eleven a molecular weight of 350,000 PDLLA-PGA copolymer 0.5kg after mixing using blow molding process, at a temperature of 200 ℃ ± 5 ℃ processed to a thickness of 0.0002 to 0.5 mm thin film, sterilized treated, for humans and animals after anti-adhesion experiment, the effect is shown in Table 1-2.

实施例十二将分子量为35万的PLGA-PGA共聚物0.5kg混合后采用吹塑成型工艺,在温度200℃±5℃下加工成厚度为0.0002~0.5毫米的薄膜,经消毒灭菌处理,用于人体及动物术后防粘连实验,其效果见表1-2。 The twelfth embodiment of the 350,000 molecular weight 0.5kg mixing PLGA-PGA copolymers using blow molding process, at a temperature of 200 ℃ ± 5 ℃ processed to a thickness of 0.0002 to 0.5 mm thin film, sterilized treated, for humans and animals after anti-adhesion experiment, the effect is shown in Table 1-2.

实施例十三将分子量为35万的PLGA-PLLA共聚物0.5kg混合后采用吹塑成型工艺,在温度200℃+5℃下加工成厚度为0.0002~0.5毫米的薄膜,经消毒灭菌处理,用于人体及动物术后防粘连实验,其效果见表1-2。 Embodiment 13 The molecular weight of 350,000 PLGA-PLLA copolymer 0.5kg after mixing using blow molding process, at a temperature of 200 ℃ + 5 ℃ processed to a thickness of 0.0002 to 0.5 mm thin film, sterilized treated, for humans and animals after anti-adhesion experiment, the effect is shown in Table 1-2.

实施例十四将分子量为35万的PGA-PLLA共聚物0.5kg混合后采用吹塑成型工艺,在温度200℃±5℃下加工成厚度为0.0002~0.5毫米的薄膜,经消毒灭菌处理,用于人体及动物术后防粘连实验,其效果见表1-2。 Embodiment 14 The molecular weight of 350,000 PGA-PLLA copolymer, a mix of 0.5kg after blow molding process, at a temperature of 200 ℃ ± 5 ℃ processed to a thickness of 0.0002 to 0.5 mm thin film, sterilized treated, for humans and animals after anti-adhesion experiment, the effect is shown in Table 1-2. ●动物实验椎板切除术是脊外科最常用的手术方式之一,下面是椎板切除术后预防硬膜外瘢痕粘连的动物实验情况1. 材料与方法1.1 动物分组选用120只成年家兔,体重为2kg~2.5kg,雌雄不限。 ● animal laminectomy spinal surgery is one of the most common surgical procedure, the following animal experiments are laminectomy case of epidural scar adhesion prevention 1. Materials and methods 1.1 Animal grouping selected 120 adult rabbits, weighing 2kg ~ 2.5kg, male or female. 随机分12组,每组10只,即几丁糖组,PLGA组,PDLLA组,PLLA组,PGA组,明胶海绵组,PDLLA-PLGA组、PDLLA-PLLA组、PDLLA-PGA组、PLGA-PGA组、PLGA-PLLA组、PGA-PLLA组,自身空白对照。 Were randomly divided into 12 groups of 10, i.e. chitosan group, group of PLGA, of PDLLA group, group of PLLA, PGA group, a gelatin sponge group, PDLLA-PLGA group, PDLLA-PLLA group, PDLLA-PGA group, PLGA-PGA group, PLGA-PLLA group, PGA-PLLA group, the control itself.

1.2 实验材料几丁糖(上海其胜生物制剂实业公司生产),明胶海绵(上海中华制药厂生产),可吸收生物膜(本发明所述制品)。 1.2 Experimental material chitosan (Shanghai which wins Biologics Co., Ltd.), a gelatin sponge (Shanghai China pharmaceutical production), can absorb the biofilm (the articles of the present invention).

1.3 实验方法1.5%戊巴比妥钠2ml/kg兔耳缘静脉注射麻碎,无菌下作兔腰背部正中切口,显露L3、L5椎板并切除,形成两个大小1cm×0.5cm的缺损,一个缺损无任何覆盖,作空白对照;另一个缺损分别覆盖几丁糖、可吸收生物膜或明胶海绵。 1.3 Experimental method 1.5% sodium pentobarbital 2ml / kg in rabbit ear vein injection crushed hemp, sterile perishable rabbit back incision portion to expose the L3, L5 laminectomy and resection, forming two defect size 1cm × 0.5cm , a defect without any covering, as control; another defect cover the chitosan, absorbable gelatin sponge or biofilm. 术后2,4,6,8及10周,每组随机选取2只兔处死,进行观察与检测。 2,4,6,8, and 10 weeks, two rabbits were randomly selected in each group were sacrificed, observation and testing.

1.4 观察内容:肉眼观察,瘢痕组织等级评定标准:0级,未见瘢痕组织或肉芽组织;I级,少量瘢痕组织或肉芽组织呈薄膜状;II级,一定数量的瘢痕组织或肉芽组织,结构疏松,质软与硬膜可分离;III级,瘢痕组织数量较多,质较硬,与硬膜粘连,不易分离;IV级,瘢痕组织数量多,完全填充缺损,质地坚硬,与硬膜广泛致密粘连。 1.4 Observations: naked eye, scar tissue grading criteria: 0, no granulation tissue or scar tissue; Class I, a small amount of scar tissue, or film-like granulation tissue; Class II, scar tissue, or a certain amount of granulation tissue, structure loose, soft and hard film separable; class III, larger number of scar tissue, hard mass, and dural adhesions, easily separated; multiple stage IV, the number of scar tissue, completely fill the defect, hard texture, and the dura mater is widely dense adhesions.

光镜观察,在处死动物的周数里,每组分别取出包括骶棘肌在内的手术段脊柱,用10%福尔马林液同步固定与脱钙2周,脱水、石蜡包埋和HE染色,光镜观察。 Light microscopy, the animals were sacrificed at weeks in each group were taken out operation comprises sacral spine, including muscle, with 10% formalin and decalcified two weeks synchronized fixed, dehydrated, embedded in paraffin and HE staining, light microscope.

透射电镜观察,分别取术后2,4及8周的样本紧靠硬脊膜处的瘢痕组织,经固定漂洗、包埋后,制成超薄切片,透射电镜观察。 TEM, samples were taken after 2, 4 and 8 weeks at a close dura scar tissue, rinsed immobilized, after embedding, ultrathin sections made, transmission electron microscopy.

1.5 统计学处理实验获得的数据采用多个样本比较(KruskaiWallis)和样本间两两比较秩和检验(Wilcoxon),检验水准α=0.05。 1.5 Statistical data processing using a plurality of samples obtained from experiments comparing (KruskaiWallis) pairwise comparison between samples and rank sum test (Wilcoxon), significance level α = 0.05.

2.结果瘢痕组织粘连分级及统计学处理(情况见表一)各组瘢痕组织粘连分级情况见附表1。 2. Results grading adhesions and scar tissue statistical (in Table 1) Each group of scar tissue adhesion. See Table 1 grade. 每组间两两比较,几丁糖组与各实验组间无显著性差异(P>0.05),但分别与明胶海绵组和各组空白对照比较有显著性差异(P<0.05)。 Pairwise comparison between each group, no significant difference (P> 0.05) between the group and chitosan experimental groups, but there were significant differences (P <0.05) compared with Gelfoam group and blank control groups.

表一 各组硬膜外瘢痕粘连分级(n=120,空白对照120例)粘连分级组 别0级 I级~II级 III级~IV级几丁糖组 9 1 0PDLLA 10 0 0PLGA 9 1 0PLLA 9 1 0PGA 8 2 0PDLLA-PLGA 8 2 0PDLLA-PLLA 9 1 0PDLLA-PGA 9 1 0PLGA-PLLA 8 2 0PLGA-PGA 8 2 0PLLA-PGA 9 1 0明胶海绵 0 0 10空白对照 0 27 93合计 96 41 103●人体实施采用实施例一~实施例十四的可吸收性生物膜逐一对人体各手术部位进行术后防粘连实验,其结果见表2。 Table epidural adhesion rating of each group (n = 120, placebo 120 cases) Group adhesion rating 0 grade I grade II grade III grade ~ ~ IV chitin group 9 1 0PDLLA 10 0 0PLGA 9 1 0PLLA 9 1 0PGA 8 2 0PDLLA-PLGA 8 2 0PDLLA-PLLA 9 1 0PDLLA-PGA 9 1 0PLGA-PLLA 8 2 0PLGA-PGA 8 2 0PLLA-PGA 9 1 0 gelfoam 0010 blank control 02 793 total 96 41 103 ● the absorbent body may be implemented using embodiments fourth embodiment biofilm embodiment of a ~ individually for each body postoperative surgical site antiblocking experimental results shown in Table 2.

表2 防粘膜人体I期临床预试一览表 Table I List pretest release film human clinical 2

*1:A.表示采用MRl、CT的检测方法;B.表示采用B超、X光的检测方法。 . * 1: A represents use of MRl, CT detection method; B represents B using ultrasound, X-ray detection. *2:除椎板切除观察时间为4个月外,其它均为3个月。 * 2: In addition to laminectomy observation period of four months, the other for 3 months.

Claims (1)

1.术后防粘连方法,其特征在于采用粘均分子量<50万,下述生物可降解吸收性聚合物:PLGA(聚乳酸——聚乙醇酸共聚物)、PDLLA(聚-D,L-乳酸)、PLLA(聚-L-乳酸)、PGA(聚乙醇酸)中的任意一种材料或一种材料与另一种材料的共聚物在温度180~220℃下加工成厚度为0.0002~0.5毫米的薄膜,经消毒,灭菌处理,用于术后防粘连。 1. A method after antiblock, characterized in that a viscosity-average molecular weight <500,000, following a biodegradable absorbent polymer: PLGA (polylactic acid - glycolic acid), of PDLLA (poly--D, L- lactic acid), copolymers of any one material or one material PLLA (polylactic acid -L-), the PGA (polyglycolic acid) of another material processing at a temperature of 180 ~ 220 ℃ a thickness of 0.0002 to 0.5 mm film, sterilized, sterilization treatment, for postoperative adhesion prevention.
CN 99115039 1999-07-27 1999-07-27 Post-operation adhesion preventing method CN1241442A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 99115039 CN1241442A (en) 1999-07-27 1999-07-27 Post-operation adhesion preventing method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 99115039 CN1241442A (en) 1999-07-27 1999-07-27 Post-operation adhesion preventing method

Publications (1)

Publication Number Publication Date
CN1241442A true CN1241442A (en) 2000-01-19

Family

ID=5278060

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 99115039 CN1241442A (en) 1999-07-27 1999-07-27 Post-operation adhesion preventing method

Country Status (1)

Country Link
CN (1) CN1241442A (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006023672A3 (en) * 2004-08-23 2006-10-05 Advanced Cardiovascular System Biologically absorbable polymers for implantable devices having a constant rate of degradation
CN1331913C (en) * 2002-02-05 2007-08-15 重庆永通信息工程实业有限公司 Synthesis and application of post-operative adhesion-preventing material
CN103055354A (en) * 2013-01-17 2013-04-24 中国科学院长春应用化学研究所 Biodegradable medical surgery anti-adhesion membrane and preparation method thereof
US9694116B2 (en) 2006-05-26 2017-07-04 Abbott Cardiovascular Systems Inc. Stents with radiopaque markers
US9763818B2 (en) 2010-01-30 2017-09-19 Abbott Cardiovascular Systems Inc. Method of crimping stent on catheter delivery assembly
US9827119B2 (en) 2010-01-30 2017-11-28 Abbott Cardiovascular Systems Inc. Polymer scaffolds having a low crossing profile
US9999527B2 (en) 2015-02-11 2018-06-19 Abbott Cardiovascular Systems Inc. Scaffolds having radiopaque markers
US10070975B2 (en) 2006-01-04 2018-09-11 Abbott Cardiovascular Systems Inc. Stents with radiopaque markers

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1331913C (en) * 2002-02-05 2007-08-15 重庆永通信息工程实业有限公司 Synthesis and application of post-operative adhesion-preventing material
WO2006023672A3 (en) * 2004-08-23 2006-10-05 Advanced Cardiovascular System Biologically absorbable polymers for implantable devices having a constant rate of degradation
US10070975B2 (en) 2006-01-04 2018-09-11 Abbott Cardiovascular Systems Inc. Stents with radiopaque markers
US9694116B2 (en) 2006-05-26 2017-07-04 Abbott Cardiovascular Systems Inc. Stents with radiopaque markers
US9867728B2 (en) 2010-01-30 2018-01-16 Abbott Cardiovascular Systems Inc. Method of making a stent
US9763818B2 (en) 2010-01-30 2017-09-19 Abbott Cardiovascular Systems Inc. Method of crimping stent on catheter delivery assembly
US9770351B2 (en) 2010-01-30 2017-09-26 Abbott Cardiovascular Systems Inc. Crush recoverable polymer scaffolds
US9827119B2 (en) 2010-01-30 2017-11-28 Abbott Cardiovascular Systems Inc. Polymer scaffolds having a low crossing profile
US10123894B2 (en) 2010-01-30 2018-11-13 Abbott Cardiovascular Systems Inc. Method of crimping stent on catheter delivery assembly
CN103055354B (en) * 2013-01-17 2015-10-07 中国科学院长春应用化学研究所 One biodegradable medical surgical anti-adhesion film and method
CN103055354A (en) * 2013-01-17 2013-04-24 中国科学院长春应用化学研究所 Biodegradable medical surgery anti-adhesion membrane and preparation method thereof
US9999527B2 (en) 2015-02-11 2018-06-19 Abbott Cardiovascular Systems Inc. Scaffolds having radiopaque markers

Similar Documents

Publication Publication Date Title
Bani-Hani et al. Retained surgical sponges (gossypiboma)
Suuronen et al. A 5-year in vitro and in vivo study of the biodegradation of polylactide plates
Wininger et al. Antibiotic-impregnated cement and beads for orthopedic infections.
Mendes et al. Biocompatibility testing of novel starch-based materials with potential application in orthopaedic surgery: a preliminary study
DE69629408T2 (en) absorbable polyoxaester
EP2023826B1 (en) Middle turbinate medializer
US5061281A (en) Bioresorbable polymers and implantation devices thereof
Li Hydrolytic degradation characteristics of aliphatic polyesters derived from lactic and glycolic acids
KR101061376B1 (en) Medical amphiphilic polymer
CA2239776C (en) Under tissue conditions degradable material and a method for its manufacturing
US8834522B2 (en) Biodegradable shape memory polymeric sutures
JP5796911B2 (en) Temporary stiffening mesh prosthesis
US5505952A (en) Modified synthetic cross-linked amino acid polymers and medical devices formed therefrom
JP4422028B2 (en) Biodegradable drain of medical
Pistner et al. Poly (l-lactide): a long-term degradation study in vivo: I. Biological results
Heidemann et al. Degradation of poly (D, L) lactide implants with or without addition of calciumphosphates in vivo
US20060040894A1 (en) Compositions and methods using hyaluronic acid
Laughlin et al. Resorbable plates for the fixation of mandibular fractures: a prospective study
US5641501A (en) Absorbable polymer blends
Päivärinta et al. Intraosseous cellular response to biodegradable fracture fixation screws made of polyglycolide or polylactide
US6352667B1 (en) Method of making biodegradable polymeric implants
Eglin et al. Degradable polymeric materials for osteosynthesis: tutorial
Hasırcı et al. Versatility of biodegradable biopolymers: degradability and an in vivo application
JP3043778B2 (en) Method for manufacturing a resorbable molded body and molded-type body
US6514517B2 (en) Antimicrobial coatings for medical devices

Legal Events

Date Code Title Description
C06 Publication
C10 Request of examination as to substance
C02 Deemed withdrawal of patent application after publication (patent law 2001)